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Synopsis: 
 
HIV-1 is the causative agent for AIDS and has been a major focus of research for the past 
two decades. Though there is a combination therapy in place known as the “Highly 
Active Anti-Retroviral Therapy” (HAART), its usefulness is confounded by the 
generation of escape mutants, a host of side effects, and its prohibitive cost. The most 
useful alternative would be the prevention of infection by vaccination. Vaccine research 
has been focused on the use of recombinant protein sub-units of the virus or combinations 
thereof to elicit a neutralizing response against the virus. These approaches have mostly 
resulted in a failure to generate broadly cross reactive neutralizing response against 
primary strains of the virus.  
The work reported herein is aimed at designing a rigidified version of gp120/gp120 
derivatives and understanding the scope of the various antigenic regions in gp120 in 
generating a neutralization response. 
 
Chapter one discusses some general features of the virus and the immune system. The 
general nature of AIDS, its spread and its immunological characteristics are also 
described in this chapter. 
 
Chapter two discusses the design and NMR structural analysis of gp120 bridging sheet 
peptide mimics in methanol and water. The structure of gp120 can be loosely divided into 
two domains (the outer domain and the inner domain) that are linked together by a 
discontinuous four stranded antiparallel beta sheet known as the bridging sheet. The 
bridging sheet is known to overlap with the coreceptor binding site of gp120 and hence is 
a suitable target for designing virus-entry inhibitors. 17b, a neutralizing antibody isolated 
from an infected individual, is known to bind to this region of gp120. Our aim in this part 
of the work was to design a four stranded antiparallel beta sheet, based on the sequence 
of the bridging sheet, that would contain most of the residues involved in 17b binding. 
NMR and CD studies confirmed that the peptide was well structured in methanol but the 
structure was largely lost on addition of aqueous solvent. A small population of the 
peptide was found to be well-folded in aqueous solution. 
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Chapter three discusses the design and characterization of a gp120-CD4D12 single chain. 
It is well known that the conformation of gp120 changes upon binding CD4 to expose 
cryptic epitopes, known as CD4i epitopes. In this work we report the generation of a 
single chain gp120-CD4 construct that has the cryptic epitopes exposed. The construct 
bound to 17b, a conformation specific antibody against the bridging sheet of gp120, a 
cryptic epitope, as well as a non-covalent complex of gp120:CD4D12. There was also very 
insignificant secondary structural change in gp120 upon complex formation with CD4D12 
as observed by CD spectroscopy. Immunological studies with DNA and protein 
vaccination in guinea-pigs indicated that though 17b like antibodies are generated after 
immunization, they did not contribute towards the neutralization of primary isolates of 
the virus. It was also observed that it was the anti-CD4D12 antibodies that were 
responsible for the neutralization by the sera. These studies indicated towards the 
inability of the bridging sheet to generate effective neutralization response in case of 
vaccination with gp120/CD4 complexes. 
 
Chapter four discusses the design of a mimic of the gp120/CD4 complex. Since it was 
seen from our previous work that gp120/CD4 complexes generate a large fraction of anti-
CD4 antibodies and hence are unsuitable for vaccination purposes, we generated a 
construct with the minimal binding region of CD4. The small fragment of CD4 spanning 
from 21st residue to 64th residue was inserted in the V1/V2 loop of gp120. The insertion 
site was designed based on the region of gp120 closest to this fragment and capable of 
tolerating insertions. This protein did not bind to 17b as well as gp120/CD4 complex but 
showed a higher binding compared to full length gp120. Further immunological 
characterization with this protein revealed that it was not capable of generating 
neutralizing antibodies against the virus. 
 
Chapter five discusses the design and execution of a SPR based solution phase 
competition experiment to find the solution phase binding constant of CD4 and CD4 
analogs to gp120. A major problem during the analysis of binding data obtained by SPR 
is the accurate determination of Rmax, a parameter needed to obtain an accurate 
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equilibrium dissociation constant. In this chapter we have developed a binary as well as a 
ternary solution phase SPR based assay to accurately determine a solution phase 
equilibrium binding constant. The binding constants were determined for gp120 binding 
to CD4D12 and other CD4 analogs. To confirm the validity of the assay, a control 
antigen:antibody interaction whose equilibrium dissociation constant has been 
determined by other methods has been used as a test case. 
Chapter six discusses the design and characterization of V3 peptides inserted in the loop 
regions of E. coli Thioredoxin (Trx). Trx has earlier been used to display random peptide 
libraries between the 33rd and the 34th residue. We have constructed three constructs 
where the peptide has been inserted between the 33rd and 34th residue, between the 74th 
and 75th residue and between the 84th and 85th residue. The insertion between 74th and 
75th position (74V3Trx) was found to be superior to the other two and would be a suitable 
alternative for display of a random peptide library. The binding of these constructs to 
447-52D, a V3 peptide specific antibody was characterized. These were also 
characterized immunologically, and 74V3Trx was found to generate weakly neutralizing 
activity against the MN strain of HIV-1. Competition experiments with 447-52D with 
these sera indicated that there were antibodies generated that could compete out 447-52D 
binding to gp120 but not in sufficient concentration to provide broad neutralization. 
 
Appendix 1 discusses the rational design of disulfides to stabilize proteins based on the 
analysis of naturally occurring disulfides. In our attempts to design a rigidified version of 
gp120 we had designed disulfides in gp120 based on its crystal structure. Many of these 
were disulfides that would span antiparallel adjacent strands. In order to improve the 
design principles, we analyzed naturally occurring disulfides that span antiparallel 
adjacent strands and characterized them in terms of their positional preference in a beta 
sheet. It was found that these disulfides mostly occur on edge strands and are found 
exclusively between non-hydrogen bonded registered pairs of adjacent antiparallel 
strands. Mutagenesis on Thioredoxin was performed to verify our results. It was found 
that disulfides designed between the non-hydrogen bonded pairs of antiparallel strands 
could significantly stabilize the protein whereas the ones between hydrogen bonded pairs 
destabilized the protein. 
